| breast cancer - adjuvant | breast cancer - HER2-positive | breast cancer - HR positive | ||
| breast cancer - adjuvant | es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HR-positive - 1st line (L1) | |
| trastuzumab based treatment | ||||
| docetaxel plus carboplatin with trastuzumab followed by trastuzumab | BCIRG-006 ... | |||
| doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab | BCIRG-006 ... BCIRG-006 ... | |||
| trastuzumab plus endocrine therapy | SYSUCC-002 | SYSUCC-002 | ||
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | GeparQuinto | |||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
